Amgen patent case may reshape drug patent deal landscape

A patent case involving Amgen is under scrutiny for its potential to redefine how drug patent applications are bought and used to extend monopolies. The outcome could set precedent affecting pharmaceutical patent deals broadly, with implications for drug pricing and competition.